6:29 PM
 | 
Oct 05, 2015
 |  BC Extra  |  Company News

FDA approves Alkermes' Aristada

Alkermes plc (NASDAQ:ALKS) gained $3.73 to $63.50 in after-hours trading after it said FDA approved Aristada aripiprazole lauroxil to treat schizophrenia. The company said...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >